Gonadotropin Releasing Hormone (GnRH) therapy — coverage and notification
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Coverage and notification policy for specified GnRH agonist products administered by a healthcare professional; governs medical necessity, approved indications, dosing limits, HCPCS coding, maximum units, and duration of approval for Blue Cross Blue Shield North Carolina members.
For gender incongruence (GID/GD) indications, a new requirement that the patient has sex trait modification coverage was added and a benefits limitation statement was included about potential exclusion of sex trait modification drugs under some plans.
Camcevi (leuprolide) was added for adults with advanced prostate cancer along with associated dosing and HCPCS codes C9399, J3490, J3590, and J9999 in the FDA label reference table.
Maximum units for Lupron Depot-Ped Kit were clarified to specify units by indication for non-oncology indications and earlier adjustments included adding 6-month (45 mg) single-dose formulation.
Coverage and Medical Necessity Criteria
Medical necessity criteria (by indication)
Covered when ALL of the following are met
root
indication_breast
- agent_breast: Requested agent is one of: Eligard/Vabrinty (leuprolide), Lupron Depot (7.5 mg, 22.5 mg, 30 mg, or 45 mg kits), Trelstar (triptorelin), Zoladex (goserelin), OR Lupron Depot (3.75 mg or 11.25 mg kits)
indication_CPP
- agent_CPP: Requested agent is one of: Triptodur (triptorelin), Fensolvi (leuprolide), Lupron Depot (3.75 mg or 11.25 mg) or Lupron Depot-Ped kit, OR Supprelin LA (histrelin)
indication_endometriosis
- agent_endometriosis: Requested agent is Zoladex (goserelin) OR Lupron Depot (3.75 mg or 11.25 mg) OR Lupron Depot-Ped kit
- endometriosis_history: Either patient is treatment-naive to the requested agent OR the prescriber provides total months previously treated AND total lifetime therapy with the agent is less than 12 months (medical record documentation required)
indication_GID
- coverage_for_sex_trait_modification: Patient has coverage for sex trait modification (benefit verification required)
- agent_GID: Requested agent is one of: Eligard/Vabrinty, Lupron Depot (various kits), Triptodur (triptorelin), Supprelin LA (histrelin), OR Zoladex (goserelin)
indication_prostate
- agent_prostate: Requested agent is one of: Eligard/Vabrinty (leuprolide), Lupron Depot (7.5/22.5/30/45 mg kits), Trelstar (triptorelin), Zoladex (goserelin), Camcevi (leuprolide), Camcevi ETM, OR generic Leuprolide Depot/Lutrate Depot (22.5 mg)
indication_fibroids
- agent_fibroids: Requested agent is Zoladex (goserelin) OR Lupron Depot (3.75 mg or 11.25 mg) OR Lupron Depot-Ped kit
- other_FDA_or_compendia: Patient has another FDA-approved indication for the agent and route OR an indication supported by compendia/NCCN with required documentation (medical record documentation required)
- contraindications_and_dosing: No FDA labeled contraindications AND requested dosing/quantity is within FDA labeling or, for oncologic uses, within NCCN 1 or 2A compendia-supported dosing OR, for non-oncologic uses, does not exceed the maximum units allowed for the approval duration
Coverage criteria and product-specific limitations
Policy references FDA-labeled indications and assigns HCPCS codes and maximum units by indication; criteria updated periodically by P&T committee.
See HCPCS and maximum units in FDA label reference table.
Providers must check the Member's Benefit Booklet; policy includes benefit limitation statement noting possible exclusion under some plans.
Refer to FDA label reference table (HCPCS mapping) for exact maximum units by product and indication.
Benefits for drugs used for sex trait modification in gender-affirming care may be specifically excluded under some health benefit plans. Refer to the Member's Benefit Booklet to determine whether these benefits are available for the member; coverage may vary by state. This policy includes a benefits limitation noting potential exclusion of sex trait modification drugs under some plans.
For requests related to gender identity disorder/gender dysphoria/gender incongruence, coverage under this policy requires verification that the member’s plan includes sex trait modification coverage. Providers must check the Member's Benefit Booklet and document benefit verification as part of the authorization request.
Requests that exceed FDA‑labeled dosing or duration, or that are not supported by NCCN 1 or 2A or other cited compendia for the requested indication and route, may be considered not medically necessary and may be denied.
If the member’s benefit design does not include sex trait modification services, treatment for gender incongruence/GID/GD may be denied as not covered per the Member's Benefit Booklet. Providers should confirm benefit availability before initiating therapy or submitting a prior authorization request.
HCPCS and Administration Codes
| J1952 | leuprolide mesylate (Camcevi) HCPCS |
| J1950 | leuprolide acetate for depot suspension (Lupron Depot-Ped Kit) IM |
| J9226 | histrelin acetate (Supprelin LA) 50 mg SC implant |
| J3315 | triptorelin pamoate (Trelstar) IM |
| J3316 | triptorelin pamoate (Triptodur) extended‑release IM |
| J9202 | goserelin acetate (Zoladex) SC implant |
| J1954 | leuprolide acetate depot 22.5 mg 3‑month injection (generic/Lutrate Depot reference) |
| S0353 | Oncology specific HCPCS |
| S0354 | Oncology specific HCPCS |
Prior Authorization, Documentation, and Billing Guidance
Prior authorization/notification required for listed products
Prior authorization or notification is required for the listed GnRH products; approvals are limited to specified indications, doses, HCPCS-defined units, and duration of approval. Use the HCPCS codes listed in the FDA label reference table when submitting specialty-billed claims.
HCPCS coding and unit limits for specialty billing
Bill GnRH agents with the HCPCS codes and units specified in the FDA label reference table; maximum units differ by product and indication and should not be exceeded on specialty claims.
- Camcevi (leuprolide mesylate) HCPCS = J1952 (maximum units non‑oncology = 84).
- Histrelin (Supprelin LA) HCPCS = J9226 (maximum units non‑oncology = 1; implant every 12 months).
- Triptorelin and goserelin HCPCS examples = J3315, J3316, J9202 (non‑oncology maximum units = 12 for several products).
- Oncology‑specific HCPCS include S0353/S0354 where applicable.
Dosing must align with maximum units and indication
Ensure the requested quantity aligns with the product‑specific maximum units for the approval duration; oncologic dosing must follow FDA labeling or NCCN compendia as applicable.
- For non‑oncologic indications, the requested quantity must NOT exceed the maximum units allowed for the duration of approval (see product table).
- Camcevi dosing example: 42 mg SC every 6 months (J1952); non‑oncology max units = 84.
- Histrelin implant dosing (J9226): one 50 mg implant every 12 months — maximum units non‑oncology = 1.
No explicit step therapy sequence specified
No explicit prerequisite step therapy sequence is defined in this policy; recent updates focus on product inclusion and member benefit verification rather than imposing step requirements.
- Coverage depends on indication support, dosing limits, and required documentation rather than a defined step‑therapy sequence.
- Providers should verify member benefits for gender‑affirming indications (see benefit limitation statement).
Medical record documentation of prior therapy required
Provide medical record documentation of prior treatment history for continuation or when requested for non‑FDA indications; include total months previously treated with the requested agent.
- For endometriosis continuation: prescriber must provide total number of months the patient has completed on the requested agent.
- Medical record documentation is required to support indications not on the FDA label (compendia or NCCN support).
Required documentation and FDA label / HCPCS references
Document the clinical indication, exact dosing/administration schedule, and verify the member's benefit for gender‑affirming care when applicable; reference FDA label dosing and HCPCS codes used for claims.
- Include indication and dosing (e.g., histrelin 50 mg SC implant every 12 months; HCPCS J9226) in the PA request and medical record.
- For GID/GD/gender incongruence indications, provide member benefit verification showing sex trait modification coverage as required by the January 2026 update.
Denial risk if FDA/compendia support or documentation is missing
Requests lacking FDA labeling or appropriate compendia/NCCN support for the indication and route, or missing required medical record documentation, may be denied.
- Non‑oncologic indications must be supported by compendia (AHFS, DrugDex 1/2A or NCCN 1/2A) with medical record documentation when not FDA‑labeled.
- Requests exceeding FDA‑labeled dosing/duration or without required supporting documentation can be considered not medically necessary.
Verify member sex trait modification benefit for GID/GD indications
For gender incongruence/GID/GD indications, confirm and document that the member's plan includes coverage for sex trait modification; lack of this benefit may result in denial per policy changes implemented January 2026.
- Policy explicitly added the prerequisite that the patient has sex trait modification coverage for GID/GD indications.
- Providers must refer to the Member's Benefit Booklet to verify availability of gender‑affirming drug benefits.
Initial Approval Requirements
Initial therapy
Initial approval tied to indication, agent-specific dosing, and maximum duration limits.
initial
- indication_list: Patient has one of the specified covered indications (see indications) and requested agent is appropriate for that indication
- no_contra: No FDA labeled contraindications to the requested agent
- dosing_within_limits: Requested dosing/quantity is within FDA labeled dosing for oncology or within maximum units for non-oncology for the approved duration
Initial therapy dosing
Initial dosing per FDA label where provided in the table.
HCPCS J9226.
HCPCS J3315 for Trelstar; J3316 for Triptodur.
HCPCS: J9217 for 7.5/22.5/30/45 mg; J1950 for 3.75/11.25 mg.
Continuation and Renewal Rules
Continuation therapy rules
Continuation permitted when documentation of prior therapy duration is provided and lifetime limits not exceeded.
continuation
- prior_treatment_info: Prescriber provides total number of months patient has completed on requested agent (medical record required)
- lifetime_limit_endometriosis: Total lifetime therapy with agent for endometriosis has not reached 12 months
Continuation dosing
Continuation dosing intervals referenced from FDA labeling for implanted or depot products.
HCPCS J9226; Non-oncology maximum units = 1.
HCPCS J3316; Non-oncology maximum units = 12.
HCPCS J9202; Non-oncology maximum units = 12.
Step Therapy and Prior Treatments
| Step | Requirement | Coverage impact |
|---|---|---|
| No explicit prerequisite steps defined | ||
| Coverage is determined by meeting indication-specific medical necessity (FDA labeling or NCCN/compendia support for oncologic indications) and by dosing/maximum units limits for non-oncologic indications (requested quantity must not exceed maximum units for the approval duration) | ||
| Coverage with criteria — prior authorization required; approval only if criteria and dosing/units/duration are met |
| Step | Recent updates / provider action | Coverage impact |
|---|---|---|
| No step specified | ||
| January 2026: Added requirement that patient has sex trait modification coverage for GID/GD/gender incongruence indications; providers must verify member benefits. Policy also added Camcevi ETM product inclusion and associated HCPCS/miscellaneous codes in prior updates. | ||
| Coverage contingent on benefit verification for gender‑affirming indications; if member plan excludes sex trait modification, request may be denied per member benefit design |
Product Quantity Limits and Maximum Units
Administration Setting and Billing
Administered by HCP; bill with HCPCS in appropriate sites
These products are intended for administration by a healthcare professional and are typically billed with corresponding HCPCS codes; typical sites of administration include office, infusion center, or clinic.
- Examples of settings: physician office, infusion center, clinic.
- Administration routes vary by product (SC injection/implant, IM injection) and should match billing with the correct HCPCS.
Implants administered in office/clinic per FDA label
Implantable products (e.g., histrelin SC implant, goserelin SC implant) are administered in clinic/office settings per FDA labeling; record the route (SC implant or IM injection) and bill the matching HCPCS.
Clinical Background
Gonadotropin‑releasing hormone (GnRH) agonists — including leuprolide, triptorelin, histrelin, and goserelin — are used to suppress gonadal hormone production for a variety of hormone‑dependent conditions. Common indications referenced in the policy include prostate and breast cancer, pediatric central precocious puberty (CPP), endometriosis, uterine fibroids, and, where benefits permit, management of gender dysphoria/gender incongruence. Duration limits in the policy reflect indication‑specific safety considerations (for example, limits intended to reduce long‑term adverse effects such as bone mineral density loss).
Definitions and Approval Durations
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.